

Title: Comparative Pharmacology of BW B1090U in the Rhesus Monkey

Authors: John J. Savarese, M.D., William B. Wastila, Ph.D., Hassan A. El-Sayad, Ph.D., Ralph Scott, M.D., Margaret Gargarian, M.D., Geoffrey Beemer, M.D., Salvatore J. Basta, M.D., N. Sunder, M.D.

Affiliation: Anesthesia Laboratories, Department of Anaesthesia, Harvard Medical School at Massachusetts General Hospital, Boston, MA and Department of Pharmacology, Wellcome Research Laboratories, Burroughs Wellcome Co., Research Triangle Park, NC

Introduction: In 1979¹ we described the preclinical pharmacology in the rhesus monkey of BW 785U, a short-acting, nondepolarizing ester neuromuscular blocking agent. During a brief clinical trial, the neuromuscular blocking activity of BW 785U was indeed very short. A hypotensive property had been noted in animals at the ED95 and higher doses. This effect, apparently due to histamine release, was much more prominent in humans, however,² and forced the cancellation of further trials. Additional structure-activity studies have since led to the development of BW B 1090U, a more potent ester material also showing a brief nondepolarizing blocking action. In this report we summarize the neuromuscular and cardiovascular effects of BWB1090U in the rhesus monkey, a species which we consider a good indicator of the actions of such substances in humans.

Methods: Adult rhesus monkeys (n=6) of either sex weighing 8-13 kg were anesthetized with thiopental 30 mg/kg and diazepam 1 mg/kg I.M. The trachea was intubated without a relaxant and anesthesia was maintained with halothane (0.5-1.0%) in N₂O/O₂ (70:30 mixture). Arterial pressure, heart rate and the twitch of the tibialis anterior, indirectly elicited at 0.15 Hz, were continuously recorded. Ventilation was controlled to maintain normal arterial gas values. Dose-response curves for neuromuscular blockade and cardiovascular effect were constructed. Appropriate statistical comparisons were made by t-test, analysis of variance, or linear regression on probit values.

In five separate experiments, the neuromuscular and cardiovascular effects of a very large dose of BWB1090U (0.2 mg/kg, or 5xED95) were noted when BWB 1090U was given as a first-bolus to virgin preparations. Ninety-five percent block was then re-established and maintained by continuous infusion for two hours. Recovery times from bolus doses and infusion were compared.

Hydrolysis rate *in vitro* by human plasma cholinesterase was determined.

Results: The hydrolysis rate was approximately 90% of that of succinylcholine.

The ED95 was 0.04 mg/kg. The duration of action at ED95 was 9-12 min, at 2.5xED95 12-15 min, and at 5xED95 14-20 min. Recovery rates are summarized in Table 1. The block showed fade of tetanus and train-of-four and was antagonized by anticholinesterases.


Table 1
Onset and Recovery Rates from BWB1090U*

Dose (mg/kg)	ED95 Multiple and % Block	Onset (min)	Recovery Time (min)	
			25-75%	5-95%
0.04	95	1.7	3.4	8.5
0.10	100	1.4	3.5	8.6
0.20	100	1.0	4.1	9.1
2-hr infusion at 95% Block			3.2	9.1

*SE's omitted for space

Cardiovascular changes became significant at 0.80 mg/kg (20xED95) (Fig 1). Cardiovascular effects after 5xED95 (0.2 mg/kg) when given either as the fourth dose in a series or as the first dose to a virgin preparation were not different and did not differ significantly from control values. Changes at 0.8 mg/kg were accompanied by facial erythema, showed tachyphylaxis, and were inhibited by H₁ and H₂ blockers.

Figure 1



Discussion and Conclusion: Like BW 785U, BW B 1090U is a short-acting nondepolarizing agent. Its safety margin is ten times as great as that of BW 785U. The duration of action is about one-third to one-half that of atracurium and vecuronium in the monkey. BWB1090U seems worthy of clinical trial.

References:

1. Savarese JJ, Wastila WB: Anesthesiology 51:S277, 1979.
2. Rosow CE et al: Anesthesiology 53:S270, 1980.
3. Marshall IG et al: Br J Anaesth. 52:11S, 1980.
4. Hughes R, Chapple DJ: Br J Anaesth 53:31, 1981.